Telcare receives CE Mark approval to market mHealth glucose meter in the European Union

Telcare, Inc., the leader in mobile diabetes management solutions, today announced it has received CE Mark approval to market its cellular-enabled blood glucose meter (BGM), the first FDA-cleared mHealth glucose meter, in the European Union. The announcement coincides with the World Health Conference and Exhibition where Telcare's Co-founder, Vice Chairman, and CEO, Prof. Jonathan Javitt, will be a featured presenter.

“We are excited to expand our reach of innovative, comprehensive diabetes management solutions to the European Union”

"We are excited to expand our reach of innovative, comprehensive diabetes management solutions to the European Union," says Dr. Javitt. "Diabetes will affect one in three people born after the year 2000 and has reached pandemic proportions world-wide. Our mobile platform unlocks the power of clinical data and creates multiple engagement points amongst those involved in an individual's care to help minimize complications and improve health outcomes."

More than 360 million people are currently living with diabetes, with this number expected to escalate to 552 million by 2030. Although the complications of diabetes can be prevented through daily monitoring and control of blood sugar, the World Health Organization estimates that 8,700 people are still dying daily from the disease. Telcare's BGM offers an innovative approach to managing the impact of diabetes by liberating data from blood glucose readings and enabling the observation and evaluation of self-management behavior across an entire population.

By leveraging cellular-enabled mHealth tools to securely capture, store and share real-time clinical data, the BGM enables care teams to access the actionable data needed to identify at-risk individuals, make targeted and informed interventions and prevent complications. Evolving partnerships allow Telcare's BGM to further assist and engage patients and their caregivers by building additional connections to biometric data. Telcare's recent partnership with Qualcomm Life's 2net cloud based platform allows the BGM to reliably deliver its data to integrated portals and databases designed to increase security and interoperability.

To learn more about how Telcare's BGM provides a fresh alternative to the management and care of individuals living with diabetes visit them in Qualcomm Booth 1101 at the World Health Conference and Exhibition, May 13-15, 2013, in Dublin. Dr. Javitt will also be speaking on Monday, May 13 at 13:30 as part of the panel entitled "Changing the Care Paradigm - mHealth Enhancing Treatment of Chronic Care."